NCT06574347View on ClinicalTrials.gov

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 7, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

July 31, 2027

Conditions
Non-Small-Cell Lung Cancer
Interventions
DRUG

Vebreltinib

Subjects will receive Vebreltinib orally twice per day (BID).

DRUG

Osimertinib

Subjects will receive Osimertinib 80mg orally once per day (QD).

DRUG

PLB1004

Subjects will receive PLB1004 80mg orally once per day (QD).

Trial Locations (1)

510080

RECRUITING

Guangdong Provincial People's Hospital, Guangzhou

All Listed Sponsors
lead

Avistone Biotechnology Co., Ltd.

INDUSTRY